



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



TC-S 7005

Cat. No.:	HY-108597
CAS No.:	1082739-92-1
Molecular Formula:	C ₂₁ H ₁₇ N ₃ O ₃
Molecular Weight:	359.38
Target:	Polo-like Kinase (PLK)
Pathway:	Cell Cycle/DNA Damage
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (347.82 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.7826 mL	13.9128 mL	27.8257 mL
	5 mM		0.5565 mL	2.7826 mL	5.5651 mL
	10 mM		0.2783 mL	1.3913 mL	2.7826 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

TC-S 7005 is a Polo-like kinases (Plks) inhibitor with IC₅₀s of 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively^[1].

IC₅₀ & Target

PLK2 4 nM (IC ₅₀)	PLK3 24 nM (IC ₅₀)	PLK1 214 nM (IC ₅₀)
----------------------------------	-----------------------------------	------------------------------------

In Vitro

TC-S 7005 markedly induces myofibroblast differentiation and reduces fibroblast proliferation rates^[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay^[2]

Cell Line:	Primary human SR fibroblasts
Concentration:	1 μM
Incubation Time:	7 days
Result:	Markedly induced myofibroblast differentiation and reduced fibroblast proliferation rates.

CUSTOMER VALIDATION

- Exp Cell Res. 2022 May 4.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Hanan EJ, et al. Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors. Bioorg Med Chem Lett. 2008 Oct 1;18(19):5186-9.
- [2]. Stephan Reinhard Künzel, et al. Hypoxia-induced epigenetic silencing of polo-like kinase 2 promotes fibrosis in atrial fibrillation. bioRxiv 445098

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA